These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 22217510

  • 1. A microarray study on the effect of four hormone therapy regimens on gene transcription in whole blood from healthy postmenopausal women.
    Dahm AE, Eilertsen AL, Goeman J, Olstad OK, Ovstebø R, Kierulf P, Mowinckel MC, Skretting G, Sandset PM.
    Thromb Res; 2012 Jul; 130(1):45-51. PubMed ID: 22217510
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis.
    Eilertsen AL, Sandvik L, Mowinckel MC, Andersen TO, Qvigstad E, Sandset PM.
    Thromb Res; 2007 Jul; 120(3):371-9. PubMed ID: 17156824
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
    Christodoulakos G, Lambrinoudaki I, Panoulis C, Sioulas V, Rizos D, Caramalis G, Botsis D, Creatsas G.
    Maturitas; 2005 Apr 11; 50(4):321-30. PubMed ID: 15780533
    [Abstract] [Full Text] [Related]

  • 6. Digitized assessment of mammographic breast density--effects of continuous combined hormone therapy, tibolone and black cohosh compared to placebo.
    Lundström E, Hirschberg AL, Söderqvist G.
    Maturitas; 2011 Dec 11; 70(4):361-4. PubMed ID: 21958943
    [Abstract] [Full Text] [Related]

  • 7. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
    Eilertsen AL, Liestøl S, Mowinckel MC, Hemker HC, Sandset PM.
    Thromb Haemost; 2007 Jun 11; 97(6):938-43. PubMed ID: 17549295
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Circulating leptin and ghrelin are differentially influenced by estrogen/progestin therapy and raloxifene.
    Lambrinoudaki IV, Christodoulakos GE, Economou EV, Vlachou SA, Panoulis CP, Alexandrou AP, Kouskouni EE, Creatsas GC.
    Maturitas; 2008 Jan 20; 59(1):62-71. PubMed ID: 18164562
    [Abstract] [Full Text] [Related]

  • 11. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation.
    Eilertsen AL, Qvigstad E, Andersen TO, Sandvik L, Sandset PM.
    Maturitas; 2006 Oct 20; 55(3):278-87. PubMed ID: 16713143
    [Abstract] [Full Text] [Related]

  • 12. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
    Christodoulakos GE, Botsis DS, Lambrinoudaki IV, Papagianni VD, Panoulis CP, Creatsa MG, Alexandrou AP, Augoulea AD, Dendrinos SG, Creatsas GC.
    Maturitas; 2006 Mar 20; 53(4):413-23. PubMed ID: 16140483
    [Abstract] [Full Text] [Related]

  • 13. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC, Christodoulakos GE, Lambrinoudaki IV, Dalamanga A, Alexandrou AP, Bramis J, Bastounis E, Creatsas GC.
    Climacteric; 2007 Oct 20; 10(5):400-7. PubMed ID: 17852143
    [Abstract] [Full Text] [Related]

  • 14. Does hormone therapy, tibolone or raloxifene modify VEGF expression in cervical epithelial cells?
    Sioulas VD, Politi E, Rizos D, Augoulea A, Kyroudi A, Sergentanis TN, Panoulis C, Aravantinos L, Creatsa M, Lambrinoudaki I.
    Climacteric; 2012 Apr 20; 15(2):181-5. PubMed ID: 22066937
    [Abstract] [Full Text] [Related]

  • 15. Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-1 are differentially suppressed by hormone therapy and raloxifene.
    Christodoulakos GE, Lambrinoudaki IV, Economou EV, Papadias C, Vitoratos N, Panoulis CP, Kouskouni EE, Vlachou SA, Creatsas GC.
    Atherosclerosis; 2007 Jul 20; 193(1):142-50. PubMed ID: 16842799
    [Abstract] [Full Text] [Related]

  • 16. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N, Genazzani AD, Bernardi F, Casarosa E, Pieri M, Palumbo M, Picciarelli G, Gabbanini M, Luisi M, Genazzani AR.
    Gynecol Endocrinol; 2005 Mar 20; 20(3):144-9. PubMed ID: 16019353
    [Abstract] [Full Text] [Related]

  • 17. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
    Johannisson E, Holinka CF, Arrenbrecht S.
    Int J Fertil Womens Med; 1997 Mar 20; 42 Suppl 2():388-98. PubMed ID: 9397386
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women.
    Stuedal A, Ma H, Bjørndal H, Ursin G.
    Climacteric; 2009 Jun 20; 12(3):248-58. PubMed ID: 19387884
    [Abstract] [Full Text] [Related]

  • 20. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
    Hammar ML, van de Weijer P, Franke HR, Pornel B, von Mauw EM, Nijland EA, TOTAL Study Investigators Group.
    BJOG; 2007 Dec 20; 114(12):1522-9. PubMed ID: 17995496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.